PMID- 31196185
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Jun 13
TI  - HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal 
      stromal cells: a two-site study.
PG  - 164
LID - 10.1186/s13287-019-1279-9 [doi]
LID - 164
AB  - BACKGROUND: Contrary to the minimal criteria proposed by the International 
      Society for Cell and Gene Therapy for defining multipotent mesenchymal stromal 
      cells (MSC), human leukocyte antigen (HLA)-DR expression is largely unpredictable 
      in ex vivo-expanded clinical-grade cultures. Although activation of MSC in 
      culture does not appear to affect their functionality, a large study 
      investigating the impact of HLA-DR expression on cell identity and potency is 
      still missing in the literature. METHODS: A retrospective analysis of HLA-DR 
      expression in 130 clinical batches of bone marrow (BM)-MSC from two independent 
      Good Manufacturing Practice-compliant production facilities was performed in 
      order to identify the consequences on critical quality attributes as well as 
      potential activation cues and dynamics of MSC activation in culture. RESULTS: 
      HLA-DR(+) cells in culture were confirmed to maintain fibroblastic morphology, 
      mesenchymal phenotype identity, multipotency in vitro, and immunomodulatory 
      capacity. Interestingly, the use of either human sera or platelet lysate 
      supplements resulted in similar results. CONCLUSIONS: HLA-DR expression should be 
      considered informative rather than as a criterion to define MSC. Further work is 
      still required to understand the impact of HLA-DR expression in the context of 
      product specifications on BM-MSC qualities for clinical use in specific 
      indications.
FAU - Grau-Vorster, Marta
AU  - Grau-Vorster M
AD  - Servei de Terapia Cel.lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i 
      Jorda, Passeig Taulat, 116, 08005, Barcelona, Spain.
AD  - Transfusion Medicine Group, Vall d'Hebron Research Institute (VHIR), Universitat 
      Autonoma de Barcelona, Passeig de la Vall d'Hebron 129-139, 08035, Barcelona, 
      Spain.
FAU - Laitinen, Anita
AU  - Laitinen A
AD  - Finnish Red Cross Blood Service, Advanced Cell Therapy Centre, Kivihaantie 7, 
      FIN-00310, Helsinki, Finland.
FAU - Nystedt, Johanna
AU  - Nystedt J
AD  - Finnish Red Cross Blood Service, Advanced Cell Therapy Centre, Kivihaantie 7, 
      FIN-00310, Helsinki, Finland. johanna.nystedt@gmail.com.
FAU - Vives, Joaquim
AU  - Vives J
AUID- ORCID: 0000-0001-9719-5235
AD  - Servei de Terapia Cel.lular, Banc de Sang i Teixits, Edifici Dr. Frederic Duran i 
      Jorda, Passeig Taulat, 116, 08005, Barcelona, Spain. jvives@bst.cat.
AD  - Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute 
      (VHIR), Universitat Autonoma de Barcelona, Passeig de la Vall d'Hebron 129-139, 
      08035, Barcelona, Spain. jvives@bst.cat.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Passeig de la Vall 
      d'Hebron 129-139, 08035, Barcelona, Spain. jvives@bst.cat.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190613
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (HLA-DR Antigens)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Apoptosis/drug effects/physiology
MH  - Bone Marrow Cells/drug effects/*metabolism
MH  - Cell Differentiation/drug effects/physiology
MH  - Cell Survival/drug effects/physiology
MH  - Cell- and Tissue-Based Therapy
MH  - Cells, Cultured
MH  - HLA-DR Antigens/*metabolism
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - Mesenchymal Stem Cells/drug effects/metabolism
MH  - Retrospective Studies
PMC - PMC6567533
OTO - NOTNLM
OT  - Cell culture
OT  - Cellular therapy
OT  - HLA-DR
OT  - Identity
OT  - Multipotent mesenchymal stromal cell
OT  - Potency
OT  - Quality compliance
COIS- The authors declare that they have no competing interests.
EDAT- 2019/06/15 06:00
MHDA- 2020/07/01 06:00
PMCR- 2019/06/13
CRDT- 2019/06/15 06:00
PHST- 2019/04/05 00:00 [received]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/05/13 00:00 [revised]
PHST- 2019/06/15 06:00 [entrez]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/06/13 00:00 [pmc-release]
AID - 10.1186/s13287-019-1279-9 [pii]
AID - 1279 [pii]
AID - 10.1186/s13287-019-1279-9 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2019 Jun 13;10(1):164. doi: 10.1186/s13287-019-1279-9.